COVID-19 vaccines are likely to drive lasting change in vaccine trade as they become a key factor in global diploma… https://t.co/Gz8Y5dr6hY
Impact of passing through rebates at the POS for diabetes medicines
Diabetes imposes a significant economic burden on Medicare, at a cost of more than $100 billion annually. Adherence to prescription medicines to treat diabetes is associated with better disease management and lower overall health care spending, yet high beneficiary out-of-pocket (OOP) costs are a common barrier to proper adherence. Passing through a share of negotiated manufacturer rebates to patients at the point of sale (POS) is a recently debated approach to lower patient OOP costs, but little attention has been paid to its potential to improve adherence and generate downstream savings.
To fill this critical data gap, we modeled the effects of passing through rebates at POS on Medicare Parts A and B spending as a result of improved adherence. This is the first research to quantify these effects. We estimate that for each beneficiary using brand diabetes medicines in the Part D coverage gap or catastrophic phase, passing through a portion of rebates at the POS would reduce overall per beneficiary healthcare spending by $1,352 and lower patient OOP spending by $367 in one year. Over the next 10 years, we project that passing through rebates at the POS for diabetes medicines could reduce total medical spending by approximately $20 billion. These findings highlight the capability of passing through rebates to not only improve access to recommended medicines, but also to improve health outcomes and reduce overall healthcare spending.
These results suggest that the adherence improvements resulting from passing through a portion of rebates could generate substantial savings across the entire Medicare program.
Additional details are available in the complete report. This research is supported by funding from Pharmaceutical Research and Manufacturers of America (PhRMA).
- What the Aduhelm backlash may mean for pharma pricing in the ‘new normal’
- Vaccine trade becomes a key factor in global diplomacy
- Germany’s ESG Law: A case study for new pharma pricing model
- Canada's PMPRB reform delays add uncertainty
- Industry hopes dashed after EU compromises to squeeze through cross border HTA agreement
- Delytact: The world's first oncolytic virotherapy for brain cancer
- Reimbursement outcomes for combination therapies in breast cancer
- Northern Ireland: A case study for drug pricing controls vs free pricing
Are you ready for what's next? Fast-evolving trends are part of the increasingly complicated factors impacting pric… https://t.co/fXCJRwWnio
The government of Canada has once again decided to delay implementation of the major drug pricing reforms that were… https://t.co/iIxnCAw8dU